Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Avalo Therapeutics, Inc. | cerc_exh991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 5, 2016
Cerecor Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
|
001-37590 |
|
45-0705648 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer Identification No.) |
|
400 E. Pratt Street Suite 606 Baltimore, Maryland |
|
21202 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (410) 522-8707
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01.Other Events.
On December 5, 2016, Cerecor Inc. (the “Company”) issued a press release in connection with the reporting of the results from its Phase 2 clinical trial with CERC-501 for nicotine withdrawal. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
|
99.1 |
|
Press Release, dated December 5, 2016, entitled “Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal.” |
|
|
|
|
|
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Cerecor Inc. |
|
|
|
|
|
|
|
|
|
By: |
/s/ Uli Hacksell |
|
|
|
|
Uli Hacksell |
|
|
|
|
President and Chief Executive Officer |
Date: December 5, 2016
3
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
|
99.1 |
|
Press Release, dated December 5, 2016, entitled “Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal.” |
|
|
|
|
|
|
4